Imiquimod Formulation with Fatty Acid Penetration Enhancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical and transdermal delivery methods for imiquimod are inefficient, requiring longer treatment durations for conditions like Type I and II Herpes simplex infections, actinic keratosis, and superficial basal cell carcinoma, and can cause skin irritation.
Innovation Solution
A pharmaceutical formulation containing 2-4% imiquimod combined with fatty acids like isostearic, linoleic, or oleic acid, in creams, ointments, foams, gels, or pressure-sensitive adhesive compositions, which enhances skin penetration and reduces irritation, allowing for shorter treatment durations and increased frequency of applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If current topical and transdermal delivery methods for imiquimod are used, then treatment can be administered, but skin penetration is inefficient and treatment duration is prolonged
Solution Approach 1:
The patent uses fatty acids (oleic acid, isostearic acid, linoleic acid) as intermediary substances to facilitate the penetration of imiquimod through the skin. These fatty acids act as penetration enhancers that temporarily disrupt the skin barrier, allowing the drug to pass through more efficiently and reduce treatment duration.
Solution Approach 2:
The patent changes the physical and chemical parameters of the delivery system by incorporating specific fatty acids that alter the skin's permeability characteristics. This enables faster drug penetration without changing the imiquimod molecule itself, thereby reducing the overall treatment time while maintaining efficacy.
2Productivity
If higher doses of imiquimod are used to shorten treatment duration, then productivity increases, but skin irritation worsens
Solution Approach 1:
Fatty acids serve as mediators that enable effective drug delivery at lower concentrations by enhancing penetration. This intermediary approach allows the system to achieve therapeutic efficacy with reduced imiquimod dosing, thereby maintaining treatment efficiency while minimizing skin irritation and adverse effects.
Solution Approach 2:
The patent optimizes the concentration parameters of imiquimod in the formulation by combining it with fatty acids. This parameter optimization allows lower drug concentrations to achieve the same therapeutic effect, reducing skin irritation while maintaining treatment productivity through improved bioavailability.
3Loss of time
If treatment frequency is increased to reduce overall treatment duration, then loss of time decreases, but skin irritation increases
Solution Approach 1:
The fatty acid intermediaries enable the skin to tolerate more frequent applications by reducing the irritant effect of each individual dose. They facilitate gentler drug delivery that allows for increased application frequency without compounding skin damage, thereby reducing total treatment duration while controlling irritation.
4Ease of manufacture
If conventional formulations are used, then manufacturing is simple, but skin penetration and treatment effectiveness are insufficient
Solution Approach 1:
The patent creates a composite formulation by combining imiquimod with fatty acids (oleic acid, isostearic acid, or linoleic acid). This composite approach enhances treatment effectiveness through improved skin penetration while maintaining relatively simple manufacturing processes, as the components are mixed in standard pharmaceutical formulations without complex synthesis steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves at least 10% skin penetration of imiquimod within 24 hours, reducing treatment duration and frequency while minimizing skin irritation, effectively treating viral infections and inducing interferon biosynthesis.
Implementation Method 1
a pharmaceutically acceptable vehicle for imiquimod, which vehicle comprises a fatty acid, such as isostearic acid, linoleic acid, oleic acid, super purified oleic acid (an oleic acid having low polar impurities such as peroxides) and a combination thereof... the formulation provides a penetration of the agent of at least about 10% (and preferably at least about 15%) of the total amount of the agent contained in the formulation in 24 hours
Data Source
AI summary
Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).